Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada.

Trial Profile

Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Aciclovir; Cetirizine; Esomeprazole; Ibuprofen; Methylprednisolone; Paracetamol; Ranitidine
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms EMERALD
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 08 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2015 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrial.gov.
    • 15 Jun 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top